Formula1.jpg (Formula1)
Ketorolac Tromethamine Injection, Solution
Product Images NDC 0404-9998
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Ketorolac Tromethamine (NDC 0404-9998). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Henry Schein, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image1.jpg (Image1)
Table 1 provides approximate average pharmacokinetic parameters for Ketorolac Tromethamine administered orally, intramuscularly, and intravenously. It includes parameters such as bioavailability, time to maximum concentration (T max), maximum concentration (C max), as well as steady-state levels at different dose levels. The table offers insights into the pharmacokinetics of Ketorolac Tromethamine for doses ranging from 10mg to 60mg, showcasing values for bioavailability, C max, C min, and volume of distribution.*
Image2.jpg (Image2)
This text contains information related to pharmacokinetic studies, including data on dose metabolized, excretion in feces and urine, plasma protein binding, time-to-peak plasma concentration, peak and trough plasma concentrations, volume of distribution, and average plasma concentration in different types of pharmacokinetic studies. The values presented are derived from studies conducted in normal volunteers and include information on the recommended single dose and mean simulated values from observed data.*
Image3.jpg (Image3)
Image4.jpg (Image4)
This text presents a list of gastrointestinal (GI) experiences, including symptoms like abdominal pain, constipation, diarrhea, dyspepsia, flatulence, fullness, ulcers, heartburn, nausea, stomatitis, and vomiting. Other experiences mentioned are abnormal renal function, anemia, dizziness, drowsiness, edema, elevated liver enzymes, headaches, hypertension, increased bleeding time, injection site pain, pruritus, purpura, rashes, tinnitus, and sweating. It provides an overview of potential side effects or symptoms related to a medical condition or treatment.*
Image5.jpg (Image5)
This table shows the incidence of clinically serious G.I. bleeding related to age, total daily dose, and history of G.I. perforation, ulcer, bleeding after up to 5 days of treatment with Ketorolac Tromethamine Injection. The data is divided into two groups: A. Adult Patients without History of PUB, and B. Adult Patients with History of PUB. For each group, the percentage of G.I. bleeding is shown based on different age ranges and total daily doses of Ketorolac Tromethamine Injection.*
Image6.jpg (Image6)
This is information about Ketorolac Tromethamine Injection USP offered in different concentrations and packaging sizes. The product is available in single-dose vials with varying strengths of 15 mg/mL, 30 mg/mL, and 60 mg/2 mL. Each carton contains 25 vials of the respective concentration.*
Label1.jpg (Label1)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
